Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has provided a corporate and operational update highlighting continued progress in its clinical development program, manufacturing activities, regulatory initiatives, financing strategy, and commercialization efforts. The company reported positive six-month results from its first-in-human (FIH) study, which support advancement to Group Two clinical surgeries.
The six-month follow-up data from Group One patients demonstrated encouraging safety and performance outcomes, with successful implantation procedures and favorable post-operative results. The study continues to achieve its primary objectives related to safety, lens delivery, and distance vision correction. Notably, one patient previously considered legally blind is now qualified to drive, reflecting meaningful improvements in vision and quality of life.
Based on these positive outcomes, Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, known as the Ocumetics Lens. The redesigned lens incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability, and accommodative performance. Key features include a simplified one-piece design, enhanced accommodative performance, improved manufacturing consistency, and elimination of internal interface materials—no air, water, or oil. Manufacturing of the redesigned lens has commenced with the company's German partner, Amiplant GmbH, in preparation for Group Two surgeries.
Group Two surgeries remain on track for Q3 2026 in Mexico City under principal investigator Dr. Raphael Vasquez. All regulatory requirements necessary to proceed have been successfully completed. The company expects positive one-month results from Group Two patients to represent another significant value-creation milestone as it advances toward larger clinical studies, regulatory submissions, and eventual commercialization.
To support completion of the FIH study and accelerate commercialization activities, Ocumetics has launched a financing initiative. Proceeds are expected to fund Group Two surgeries, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging, advance regulatory and quality assurance programs, and continue strategic partnership initiatives. During recent investor conferences, the company conducted over 50 one-on-one meetings with institutional investors, family offices, and strategic industry participants, reflecting growing recognition of its clinical progress.
Strategic discussions continue with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities. Based on encouraging feedback, several organizations have expressed interest in reviewing additional clinical data after Group Two surgeries, with follow-up discussions tentatively scheduled for early Q4 2026.
Management believes the commercial potential of the Ocumetics Lens is validated by these discussions, as it addresses a significant unmet need in vision restoration following cataract surgery. The lens is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag.
With positive six-month clinical data, the next-generation lens design completed, manufacturing underway, regulatory milestones achieved, and strategic engagement with leading ophthalmic companies, Ocumetics believes it is well positioned to execute the next phase of its clinical development strategy. The company remains focused on successfully completing Group Two surgeries, advancing regulatory initiatives, and building strategic relationships to support long-term commercialization.
